Olesen KM, Hansen SH, Sidenius U, Schmiegelow K
Neumiller, PharmD, CDCES, FADCES, FASCP, about nuances of using SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes, and a therapy for delaying type 1 diabetes onset
So lets talk about why nausea happens, what your gut is trying to tell you, and how the right nutrition support can make a big difference
People who have previously run GLP-1 based compounds and noticed post-cycle skin changes, either laxity or reduced firmness compared to their target weight look, are strong candidates for adding GHK-Cu to their next Retatrutide cycle
Clinical trials and real-world data show that GLP-1 users typically reduce daily calorie intake by 500 to 1,000 calories compared to their baseline consumption